Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteins involved in heme metabolism in Plasmodium falciparum are central therapeutic targets for antimalarial drugs. During its intraerythrocytic stage, P. falciparum digests host hemoglobin within its acidic food vacuole, releasing large amounts of potentially toxic free heme[1][8]. To avoid toxicity, the parasite converts this free heme into inert crystalline hemozoin via specialized proteins such as the heme detoxification protein (HDP)[1], among others involved in this process[4][5]. Some antimalarial drugs—including chloroquine—act by inhibiting this conversion process; failure to sequester toxic heme results in oxidative damage and death of the parasite[4]. Artemisinin derivatives act through a distinct but related mechanism—they are activated by iron(II) or labile ferrous centers found predominantly within these same compartments rich in hemoglobin digestion products. Upon activation via cleavage of their endoperoxide bridge by Fe(II)/heme species present inside infected erythrocytes' food vacuoles, they generate highly reactive carbon-centered radicals that alkylate numerous essential parasite proteins across various cellular compartments[6]. Thus their action is pleiotropic rather than directed at a single molecular entity. Additional potential targets may be engaged depending on which partner drug is combined with artemisinins—for example inhibitors targeting mitochondrial electron transport chain components like cytochrome bc1 when using atovaquone as a partner drug[5]. Because these entries refer collectively to several related but distinct molecules/pathways—and because some mechanisms involve non-protein chemical reactivity—the term "multiple targets" here does not correspond to one canonical gene/protein product but rather encompasses an array of functionally linked molecules critical for malaria pathogenesis and therapy response. If you need structured information about individual components such as "Heme detoxification protein," "Plasmodium falciparum ferrochelatase," or specific redox-sensitive enzymes targeted by artemisinins specifically identified through chemoproteomics studies,[6] please specify so each can be mapped precisely according to your conventions.
1. Artemisinins: Activated by iron(II) or heme within the parasite food vacuole to generate cytotoxic free radicals that alkylate multiple parasite proteins[6]. These include enzymes involved in redox homeostasis, hemoglobin digestion, and other essential processes. 2. Chloroquine/Quinine: Inhibit the polymerization of toxic free heme into inert hemozoin crystals within the food vacuole[4][8]. Accumulation of toxic free heme leads to parasite death. 3. Partner drugs: Mechanisms vary—may inhibit different metabolic pathways or transporters depending on the compound used.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Heme metabolism proteins of Plasmodium falciparum.